Drug Trial Radar · NCT05066997
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)
Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
552
Actual
Start
Oct 19, 2021
Primary completion
Apr 10, 2026
Study completion Apr 10, 2026
Sponsor
- Lead sponsor
- OculisIndustry
- Sponsor type
- Industry
- First posted
- Oct 4, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of OCS- 01 as compared to Vehicle in participants with Diabetic Macular Edema (DME).
Conditions
- Diabetic Macular Edema
Interventions
Dexamethasone ophthalmic suspension (OCS-01)Drug
Stage 1: Participants will be dosed with one eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 6 weeks (maintenance phase). Stage 2: Participants will be dosed with one eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase).
VehicleDrug
Stage 1: Participants will be dosed with one eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 6 weeks (maintenance phase). Stage 2: Participant will be dosed with one eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change in BCVA (Best Corrected Visual Acuity)Time frame: Week 52
Locations
52 sites in 4 countries. Site status is shown where the registry gives one.
Arizona Retina and Vitreous Consultants
Phoenix, Arizona
Phoenix Retina Associates
Phoenix, Arizona
Retina Partners of Northwest Arkansas
Springdale, Arkansas
Retina-Vitreous Associates Medical Group
Beverly Hills, California
The Retina Partners
Encino, California
Retinal Consultants Medical Group
Modesto, California
California Eye Specialists Medical Group
Pasadena, California
California Eye Specialists Medical Group
Redlands, California
Retina Consultants of Southern California
Redlands, California
California Retina Consultants
Santa Maria, California
Retina Group Of New England
Waterford, Connecticut
Rand Eye Institute
Deerfield Beach, Florida
Florida Retina Institute
Jacksonville, Florida
MedEye Associates
Miami, Florida
Florida Retina Institute
Orlando, Florida
Retina Care Specialists
Palm Beach Gardens, Florida
East Florida Eye Institute
Stuart, Florida
Southeast Retina Center
Augusta, Georgia
Retina Associates
Elmhurst, Illinois
University Retina
Lemont, Illinois
Midwest Eye Institute
Carmel, Indiana
Cumberland Valley Retina Consultants
Hagerstown, Maryland
Retina Consultants of Minnesota
Saint Louis Park, Minnesota
The Retina Institute
St Louis, Missouri
Retina-Vitreous Surgeons of Central New York
Liverpool, New York
North Carolina Retina Associates
Wake Forest, North Carolina
Velocity (Meridian) Clinical Research
Cincinnati, Ohio
Verum Research LLC
Eugene, Oregon
Vision Research Solutions in Philadelphia
Philadelphia, Pennsylvania
Retina Consultants of Charleston
Beaufort, South Carolina
Charleston Neuroscience Institute
Ladson, South Carolina
Black Hills Regional Eye Institute
Rapid City, South Dakota
Retina Research Institute of Texas
Abilene, Texas
Retina Consultants of Austin/Austin Research Center for Retina
Austin, Texas
Texas Retina Associates
Dallas, Texas
Retina Center of Texas
Grapevine, Texas
Valley Retina Institute PA d.b.a. Gulf Coast Eye Institute
McAllen, Texas
Tyler Retina Consultants
Tyler, Texas
Strategic Clinical Research Group
Willow Park, Texas
Piedmont Eye Center
Lynchburg, Virginia
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.